Corton Capital Inc. Purchases New Shares in West Pharmaceutical Services, Inc. $WST

Corton Capital Inc. bought a new position in West Pharmaceutical Services, Inc. (NYSE:WST) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 1,006 shares of the medical instruments supplier’s stock, valued at approximately $220,000.

A number of other large investors have also recently made changes to their positions in WST. SYM FINANCIAL Corp boosted its stake in shares of West Pharmaceutical Services by 5.1% during the 2nd quarter. SYM FINANCIAL Corp now owns 1,027 shares of the medical instruments supplier’s stock worth $225,000 after purchasing an additional 50 shares during the period. Horizon Investments LLC boosted its stake in shares of West Pharmaceutical Services by 5.8% during the 1st quarter. Horizon Investments LLC now owns 1,048 shares of the medical instruments supplier’s stock worth $234,000 after purchasing an additional 57 shares during the period. Pallas Capital Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 1.0% during the 2nd quarter. Pallas Capital Advisors LLC now owns 6,333 shares of the medical instruments supplier’s stock worth $1,386,000 after purchasing an additional 62 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in shares of West Pharmaceutical Services by 22.7% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 340 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 63 shares during the period. Finally, Gen Wealth Partners Inc boosted its stake in shares of West Pharmaceutical Services by 4.1% during the 1st quarter. Gen Wealth Partners Inc now owns 1,953 shares of the medical instruments supplier’s stock worth $437,000 after purchasing an additional 77 shares during the period. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Trading Down 0.9%

NYSE WST opened at $279.51 on Tuesday. The company’s 50-day moving average price is $263.74 and its 200-day moving average price is $238.01. The company has a current ratio of 2.87, a quick ratio of 2.18 and a debt-to-equity ratio of 0.07. The stock has a market cap of $20.11 billion, a PE ratio of 41.41, a PEG ratio of 4.09 and a beta of 1.07. West Pharmaceutical Services, Inc. has a 12 month low of $187.43 and a 12 month high of $348.90.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.29. The firm had revenue of $804.60 million for the quarter, compared to analysts’ expectations of $788.42 million. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The business’s revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the prior year, the business posted $1.85 earnings per share. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. Equities research analysts forecast that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on the stock. Zacks Research cut shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, September 23rd. KeyCorp lifted their price target on shares of West Pharmaceutical Services from $325.00 to $350.00 and gave the stock an “overweight” rating in a research note on Friday, October 24th. Redburn Partners set a $311.00 price target on shares of West Pharmaceutical Services in a research note on Monday, September 15th. UBS Group lifted their price target on shares of West Pharmaceutical Services from $320.00 to $355.00 and gave the stock a “buy” rating in a research note on Friday, October 24th. Finally, TD Cowen initiated coverage on shares of West Pharmaceutical Services in a report on Wednesday, October 29th. They issued a “buy” rating and a $350.00 price target on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $349.20.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.